ABO Blood Group. Related Investigations and Their Association with Defined Pathologies

The ABO blood group system was discovered by Karl Landsteiner in 1901. Since then, scientists have speculated on an association between different pathologies and the ABO blood group system. The aim of this pilot study was to determine the significance between different blood types of the ABO blood group system and certain pathologies. We included 237 patients with known diagnosis, blood group, sex, and age in the study. As a statistical method, the Chi-square test was chosen. In some cases, a significant association between the blood groups and defined diseases could be determined. Carriers of blood group O suffered from ulcus ventriculi and gastritis (X21 = 78.629, p <0.001), colitis ulcerosa and duodenitis (X21 = 5.846, p < 0.016), whereas male patients carrying blood group A tended to contract different types of tumours. In patients with intestinal tumours, females with blood group A were more likely to develop the pathology, whereas in males, the blood group O dominated. The development of cholelithiasis was found, above all, in patients with blood group O, which differed from other research where a correlation between this pathology and blood group A was found

Tiere in der Forschung : Naturwissenschaftliche, rechtliche und ethische Aspekte

Die Ausgestaltung des Mensch-Tier-Verhältnisses gehört zu den großen normativen Herausforderungen von Ethik, Recht und Naturwissenschaften. In den gegenwärtigen Debatten herrscht weitgehend Einvernehmen darüber, dass Tiere nicht mehr als bloße Sachen zu betrachten sind, sondern Anspruch auf Rücksichtnahme haben. Bei der Forschung mit Tieren ist strittig, wie diese Rücksichtnahme praktisch auszufallen hat. Da moralische Anerkennungen nur aus der ethischen Gemeinschaft der Personen heraus formuliert werden können, wird eine asymmetrische Situation erzeugt zwischen dem Verhältnis von menschlichem Selbstinteresse und den Mutmaßungen darüber, was gut für andere animalische Lebewesen ist. Aufgrund hoher rechtlicher Hürden beim Umgang mit Probanden sowie der Vorgabe, dass klinische Anwendungen durch Tierexperimente abgesichert werden müssen, spielt die Forschung mit Tieren eine große Rolle im Rahmen der medizinischen Forschung. Der vorliegende Sachstandsbericht analysiert die Entwicklung der Tierversuchszahlen im Rahmen einer umfassenden Einführung in die Grundlagen der Forschung mit Tieren. Zusätzlich wird über den Stand bei der Erforschung von Alternativmethoden informiert. Schließlich werden die rechtlichen und ethischen Aspekte des Tierversuchs diskutiert.The arrangement of the human-animal-relationship is one of the paramount normative challenges of ethics, law, and the natural sciences. In present discussions there is a widely prevalent agreement that animals must no longer be regarded as mere things but deserve consideration. In research with animals there is no consensus as to how this consideration shall be put into practice. As moral recognitions can only be formulated out of the ethical community of persons, an asymmetrical situation is generated between the relation of human self-interest and suppositions about what is beneficial for other animals. Due to high legal hurdles in dealing with study participants and the stipulation that clinical applications must be backed up by animal testing, research with animals plays an important role in the realm of medical research. The present expert report analyses the development of the numbers in animal testing embedded in a comprehensive introduction to the foundations of research with animals. Furthermore, it informs about the state of the art of research of alternative methods and finally discusses the legal and ethical aspects of animal testing

Influence of Artificial Sweetener on Human Blood Glucose Concentration

Artificial sweeteners, such as saccharin or cyclamic acid are synthetically manufactured sweetenings. Known for their low energetic value they serve especially diabetic and adipose patients as sugar substitutes. It has been hypothesized that the substitution of sugar with artificial sweeteners may induce a decrease of the blood glucose. The aim of this study was to determine the reliability of this hypothesis by comparing the influence of regular table sugar and artificial sweeteners on the blood glucose concentration. In this pilot-study 16 patients were included suffering from adiposity, pre-diabetes and hypertension. In the sense of a cross-over design, three test trials were performed at intervals of several weeks. Each trial was followed by a test free interval. Within one test trial each patient consumed 150 ml test solution (water) that contained either 6 g of table sugar (“Kandisin”) with sweetener free serving as control group. Tests were performed within 1 hr after lunch to ensure conditions comparable to patients having a desert. Every participant had to determine their blood glucose concentration immediately before and 5, 15, 30 and 60 minutes after the intake of the test solution. For statistics an analysis of variance was performed. The data showed no significant changes in the blood glucose concentration. Neither the application of sugar (F4;60 = 1.645; p = .175) nor the consumption of an artificial sweetener (F2.068;31.023 = 1.551; p > .05) caused significant fluctuations in the blood sugar levels. Over a time frame of 60 minutes in the control group a significant decrease of the blood sugar concentration was found (F2.457;36.849 = 4.005; p = .020) as a physiological reaction during lunch digestion

Treatment of Lowland Frogs From the Spawn Stage with Homeopathically Prepared Thyroxin (10 -30

The influence of a highly diluted agitated, i.e. homeopathically prepared thyroxin solution (10-30, final concentration in the basin water 10-35 parts by weight after the first application) on metamorphosis in lowland Rana temporaria from the spawn stage on was studied. The treatment with homeopathically prepared thyroxin solution (10-30) starts at the frogspawn stage. It represents a tool to learn more about the previously standardized amphibian model, where the thyroxin solution was applied from the two- legged stage on only. Lowland frogs were pretreated by immersing spawn in an aqueous molecular thyroxin dilution (10-8 parts by weight). In later stages of development (2 to 4 legged), this has been found to speed up metamorphosis by around 15%. In accordance with the homeopathic idea of detoxication or cure, hyperstimulated animals (spawn or, in subsequence, larvae) were treated either with thyroxin that had been highly diluted and agitated in successive steps, i.e. homeopathically prepared (10-30), or analogously prepared blank solution (water). Development was monitored by documenting the number of animals that had entered the four-legged stage. It has been found that animals treated with the test solution metamorphosed more slowly than the control animals, i.e. the effect of the homeopathically prepared thyroxin was opposed to the usual effect of molecular thyroxin. The number of test animals that reached the 4- legged stage at defined points in time was slightly smaller in the group treated with homeopathically prepared thyroxin at some, but not at all points in time, compared to control. The results in this study sustain the previous multi researcher findings that highly diluted homeopathically prepared thyroxin is able to slow down metamorphosis of Rana temporaria

Future Scenarios of Nitrogen in Europe

The future effects of nitrogen in the environment will depend on the extent of nitrogen use and the practical application techniques of nitrogen in a similar way as in the past. Projections and scenarios are appropriate tools for extrapolating current knowledge into thefuture. However,these tools will not allow future system turnovers to be predicted. Approaches• In principle, scenarios of nitrogen use follow the approaches currently used for air pollution,climate ,or ecosystem projections. Short term projections (to 2030) are developed using a ‘baseline’ path of development,which considers abatement options that are consistent with European policy. For medium-term projections (to 2050) and long-term projections, the European Nitrogen Assessment (ENA) applies a ‘storyline’ approach similar to that used in the IPCC SRES scenarios. Beyond 2050 in particular, such story lines also take into account technological and behavioral shift s.Key findings/state of knowledge• The ENA distinguishes between driver-oriented and effect-oriented factors determining nitrogen use. Parameters that cause changes in nitrogen fixation or application are called drivers. In a driver-based approach, it is assumed that any variation of these parameters will also trigger a change in nitrogen pollution. In an effect-based approach, as the adverse effects of nitrogen become evident inthe environment, introduction of nitrogen abatement legislation requiring the application of more efficient abatement measuresis expected. This approach needs to rely on a target that is likely to be maintained in the future (e.g.human health). Nitrogen abatement legislation basedon such targets will aim to counter any growth in adverse environmental effects that occur as a result of increased nitrogen application.• For combustionand industry, technical fixes forabatement are available. Allscenarios agree in projecting a decrease in NOx emissions.Yet agricultural nitrogen use is expected to remain the leading cause of nitrogen release to the environment, as options to reduce emissions are limited. Thus, major changes will occur only if the extent of agricultural production changes, which may possibly be triggered by decreasing population numbers in Europe.The scenarios presented here project modest changes in NH 3 and N 2 O emissions, or nitrateleaching, but do not agree on the direction of these changes.•Agricultural activity (and thus nitrogen loads to the environment) may decrease strongly if the European population adopts a healthier‘low meat’ diet leading to lower nitrogenlosses related to animal husbandry. Change to a ‘healthy diet’ across the EU, which consists of 63% less meat and eggs, would reduce ammonia emissions from animal production by 48%. However, if an agricultural area previously used for animal feed production is utilized for biofuel crops, additional nitrogen fertilizer maybe required, which will partially offset reductions of nitrogen leakage to the environment. Major uncertainties/challenges• International trade in nitrogen-containing goods (agricultural as well as industrial) represents a key uncertainty and is difficult to project. Estimating the demand for such goods for Europe alone may not at all reflect European production and related environmental effects. The industrial use of nitrogen is alsovery poorly understood, but it is expected to continue to grow considerably. The respective environmental impacts of such products cannot be clearly discerned from statistical information.Recommendations• Scenarios need to be continuously updated in terms of economic, technical, and societal trends to reflect improved understanding of these factors. Using nitrogen budgets as tools could improve the consistency of scenarios.JRC.DDG.H.2-Climate change and air qualit

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362